Forgot password

The mission of NNECOS is to promote the highest quality care for patients with cancer and blood disorders in our region through professional networking, education, and scientific research, as well as patient advocacy and public policy.

ANNUAL MEETING SPOTLIGHT

REGISTER TODAY!

Join us October 24-25th for education, connection, and more at the beautiful Omni Mount Washington Hotel in Bretton Woods, NH.

Take advantage of Early Registration Discounts now through August 15th. Registering early ensures the best rates and optimal availability for accommodations!

SUBMIT AN ABSTRACT!

Physicians, nurse practitioners, physician assistants, nurses, allied healthcare providers, administrators, pharmacists, and post-graduate trainee members of NNECOS are eligible* to submit an abstract for the 2025 NNECOS Annual Meeting.

Submission Deadline: August 19th

Learn more & submit an abstract!

*Please note: Employees of industry are not eligible to submit an abstract.

ALL UPCOMING EDUCATIONAL OPPORTUNITIES

MCGI GENOMIC TUMOR BOARD

Wednesday, July 23rd at 12:00pm

MCGI Genomic Tumor Board

Submit a case by Friday, July 18th and/or email MCGI if you are interested in attending.

Lunchtime webinar Series

Thursday, July 31st at 12:15pm

Understanding Acute Leukemia
A Clinical Overview of AML and ALL
presented by Syndax Pharmaceuticals, Inc.*

Sara Orndoff-Snyder, MSN, RN

*Please note: employees of industry are not eligible to participate in this program

OCN Review Course

Monday, September 15th at 8am
Portland, ME


NNECOS OCN Review Course


Register by September 5th!

EDUCATIONAL DINNER PROGRAM

Monday, September 15th at 6:30pm
Portland, ME

Bispecific Antibodies in the Outpatient Setting: Eliminating Barriers & Creating Access

Yoni Resnick, PharmD

Learn more & RSVP by September 1st!

ANNUAL MEETING

NNECOS Annual Meeting
October 24-25, 2025

SPRING MEETING

Save the Date!

NNECOS Spring Meeting
April 25, 2026

RESEARCH, PROJECT & PROGRAM FUNDING


Fall Submission Deadline - September 15th


Fall Submission Deadline

October 15th


Up to $4,000 to fund your educational program.

Rolling Application Deadline

NNECOS PATIENT PHILANTHROPY


Rolling Application Deadline

Up to $3,000 per grant


Rolling Application Deadline

Up to 125, $25 grocery/cards 


OTHER NEWS & INFORMATION

NNECOS Classifieds

Visit the NNECOS Member Classifieds for more information about job listings from the following centers:

  • New England Cancer Specialists
  • UVM Cancer Center, Larner College of Medicine 

  • Dartmouth Cancer Center

  • UVM Cancer Center

REGIONAL EDUCATION

Visit the Regional Educational Programs for more information about the following upcoming programming:

Industry-Supported Programs:

  • July 17th - Understanding Acute Leukemia A Clinical Overview of AML and ALL, presented by Syndax Pharmaceuticals
  • July 18th - KISQALI: A Brief Review of Reducing the Risk of Recurrence in HR+/HER2- Early Breast Cancer, presented by Novartis

FELLOW LIAISON UPDATES

Welcome, new board fellow liaisons!


Join us in thanking our outgoing fellow liaisons & wishing them the best of luck in their future endeavors!


Drug Shortages Sign On Letter

https://asco.quorum.us/campaign/56411/

Looking Back!

Enjoy this wonderful interview with 3 of NNECOS' founding members!



SOCIAL MEDIA

 

Participate on a NNECOS Task Force


FDA Approvals & uPDATES

Latest FDA Approval

  • July 2 - FDA grants accelerated approval to linvoseltamab-gcpt for relapsed or refractory multiple myeloma
  • July 2 - FDA grants accelerated approval to sunvozertinib for metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations
  • June 23 - FDA grants accelerated approval to datopotamab deruxtecan-dlnk for EGFR-mutated non-small cell lung cancer
    June 18 - FDA approves tafasitamab-cxix for relapsed or refractory follicular lymphoma
  • June 12 - FDA approves mitomycin intravesical solution for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer
  • June 12 - FDA approves neoadjuvant and adjuvant pembrolizumab for resectable locally advanced head and neck squamous cell carcinoma
  • June 11 - FDA approves taletrectinib for ROS1-positive non-small cell lung cancer
  • June 3 - FDA approves darolutamide for metastatic castration-sensitive prostate cancer
  • May 14 - FDA grants accelerated approval to telisotuzumab vedotin-tllv for NSCLC with high c-Met protein overexpression
  • May 14 - FDA approves belzutifan for pheochromocytoma or paraganglioma
  • May 8 - FDA grants accelerated approval to the combination of avutometinib and defactinib for KRAS-mutated recurrent low-grade serous ovarian cancer


Package/Label Updates


    Code Updates

    • Claim Issue Reported 1/8/25 impacting Part B providers in Jurisdiction JK and Jurisdiction J6 - Claims with healthcare common procedure coding system (HCPCS) G2211 with date of service (DOS) 1/1/2024-9/30/2024.

    • Effective for dates of service on or after April 1, 2024, the Centers for Medicare and Medicaid Services (CMS) has assigned the following Healthcare Common Procedure Coding System (HCPCS)* J-Code for ELREXFIO (elranatamab-bccm) injection:
    J1323- Injection, elranatamab-bcmm, 1 mg

    Other Updates


    Thank You Corporate Members!


    Group Practice Members

    Because your entire team benefits
    from being a part of NNECOS!

    THANK YOU DIAMOND & PLATINUM CORPORATE MEMBERS


































    View the complete list of corporate members.

    Northern New England Clinical Oncology Society
    P.O. Box 643
    Sandown, NH 03873-0643
    Telephone (603) 887-1948
    info@nnecos.org

    This website brought to you by:


    Powered by Wild Apricot Membership Software